Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous T-cell immunotherapy
- Development stage
- Unknown
- Lead developer
- AbelZeta, Inc.
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous T-cell immunotherapy is a cell-based therapy developed by Shanghai AbelZeta Ltd. (formerly Cellular Biomedicine Group) for the treatment of advanced gastric cancer. The therapy utilizes the patient's own T lymphocytes, specifically enriched for the central memory T cell (Tcm) phenotype, which are expanded ex vivo and re-infused. Tcm cells are characterized by their high proliferative capacity, long-term persistence, and ability to differentiate into potent effector T cells upon encountering tumor antigens. This treatment is typically evaluated as part of a multimodal regimen, combined with surgery and chemotherapy, to enhance the anti-tumor immune response and prevent recurrence in patients with advanced gastric malignancies.
- Other names
- Autologous T cells-Based ImmunotherapyAutologous Central Memory T cell therapyTCM cell therapy
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on autologous T-cell immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous T-cell immunotherapy.